Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results, Beats Expectations By $0.25 EPS

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25, Zacks reports. The firm had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%.

Agios Pharmaceuticals Trading Down 5.4 %

NASDAQ AGIO traded down $1.63 during trading on Tuesday, hitting $28.34. 836,971 shares of the company's stock were exchanged, compared to its average volume of 700,115. The company has a market cap of $1.64 billion, a PE ratio of 2.50 and a beta of 0.77. Agios Pharmaceuticals has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock's 50 day moving average price is $29.60 and its two-hundred day moving average price is $37.58.

Analyst Upgrades and Downgrades

Several brokerages have commented on AGIO. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 1st. Finally, Scotiabank reduced their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.00.

Insider Activity

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of the business's stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.93% of the stock is currently owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.